Dignitana AB represents core values of innovation, compassion, and empowerment. As a global leader in scalp cooling technology, the company is dedicated to improving the quality of life for cancer patients undergoing chemotherapy. Dignitana AB focuses on providing cutting-edge solutions that minimize hair loss and boost patient self-confidence during treatment. The corporate philosophy revolves around a patient-centric approach, ensuring the utmost care and support for individuals facing this challenging journey. Dignitana AB's commitment to continuous improvement and technological advancements emphasizes their dedication to enhancing the well-being of cancer patients worldwide.

Dignitana AB is primarily present in various countries and regions. The company has a global presence, with its headquarters located in Sweden. Dignitana AB also operates in the United States, Europe, and Asia. The company's innovative scalp cooling technology, DigniCap, is used in cancer centers and hospitals worldwide, offering patients undergoing chemotherapy the opportunity to minimize hair loss. With a strong international presence, Dignitana AB continues to expand its reach and provide its groundbreaking solutions to cancer patients across the globe.

Dignitana AB, a leading medical technology company, has accomplished several significant milestones. Firstly, garnering FDA clearance in 2015 for its innovative scalp cooling system, DigniCap®, marked a major achievement in the field of cancer care. This breakthrough enabled patients undergoing chemotherapy to reduce hair loss during their treatment. Furthermore, Dignitana AB has successfully expanded its global presence by establishing partnerships with numerous prestigious medical centers and clinics worldwide. The company's commitment to research and development has resulted in continuous improvements to their scalp cooling technology. With its exceptional achievements and dedication to patients' well-being, Dignitana AB remains at the forefront of the medical industry.

Dignitana AB is a renowned company that specializes in medical technology and develops innovative solutions for cancer patients. Founded in 2000, the company's primary focus is on creating superior scalp cooling systems to minimize hair loss during chemotherapy treatments. Dignitana AB's flagship product, the DigniCap® Scalp Cooling System, has gained worldwide recognition and approval from various regulatory authorities. With its commitment to enhancing cancer patients' quality of life, Dignitana AB continues to expand its reach and establish strategic partnerships across the globe. This Swedish-based company remains dedicated to delivering advanced and effective solutions for those undergoing cancer treatment.

The main competitors of Dignitana AB in the market include Paxman Coolers Ltd. and Chemo Cold Caps Ltd. These companies offer similar scalp cooling solutions for reducing hair loss during cancer treatment. However, Dignitana AB stands out due to its innovative and patented technology, known as DigniCap, which provides precise temperature control and enhanced comfort for patients. Dignitana AB has gained significant market presence and a strong reputation for their scalp cooling system, making them a leading player in the industry.

Dignitana AB is primarily active in the healthcare and medical device industries.

The business model of Dignitana AB is focused on providing innovative medical devices and solutions for cancer patients. The company specializes in developing and marketing scalp cooling systems, such as the DigniCap, which minimize hair loss during chemotherapy treatments. By offering this cutting-edge technology, Dignitana AB aims to enhance the quality of life for cancer patients by reducing a common side effect of treatment. Their scalp cooling systems are designed to be safe, effective, and user-friendly. Dignitana AB's business model revolves around improving the overall well-being of cancer patients by providing them with a solution to maintain their self-confidence and self-esteem.

Dignitana P/E suhe on −10,47.

Dignitana KUV on 0,79.

AlleAktien kvaliteediskoor ettevõttele Dignitana on 5/10.

oodatud Dignitana käive on 109,14 mln. SEK.

oodatud Dignitana kasum on −8,22 mln. SEK.

Dignitana AB is a company dedicated to the development and provision of medical devices and solutions for the treatment of hair loss. The company offers innovative solutions to counter the severe side effects of chemotherapy patients. It is headquartered in Lund, Sweden and was founded in 2000. The company has two different business units: DigniCap and DigniTherm. DigniCap is a cooling cap that specifically prevents hair loss during chemotherapy. It is a FDA-approved device marketed in the USA through its subsidiary, Dignitana Inc. DigniTherm solutions by Dignitana are a new technology to help breast cancer patients increase their heat sensitivity during invasive treatments. This is intended to support the effectiveness of radiation therapy and reduce side effects. The cooling cap is a medical device specifically developed for patients undergoing chemotherapy. It works through a combination of cold and pressure to reduce blood flow to the scalp. This prevents chemotherapy drugs from penetrating the hair follicles and damaging the hair roots. As a result, hair loss is prevented or at least significantly reduced. DigniCap is a unique and patented product that offers a promising solution for treating hair loss as a side effect of chemotherapy. The method has received FDA approval in the USA due to excellent results in clinical trials. In Europe, DigniCap has been on the market since 2013 and has been approved in many European countries. The solution is used in many prestigious hospitals and clinics worldwide. DigniTherm is another innovation by the company that increases the body temperature of patients to support the effectiveness of radiation therapy during cancer treatment. The solution is also used in other dimensions to increase body temperature. Heated clothing, mats, etc. are in development or being launched. The target audience of the company is clinics and hospitals operating in the oncology field. It is also an important partner for insurance companies and other healthcare service providers. The company's business activity is focused on the development and marketing of products that support patients undergoing cancer treatments. The business model includes the sale of devices as well as service and support for the products. Additionally, Dignitana develops future-oriented technologies with a focus on medical needs. In summary, Dignitana is an innovative medical technology company specializing in the development of medical devices for the oncology field that reduce the side effects of chemotherapy and radiation therapy. The business units DigniCap and DigniTherm are unique solutions that meet the needs of patients and medical personnel. The company's expertise in the development and provision of medical devices and solutions provides unique value to customers and partners worldwide.

Dignitana maksab dividendi 0 SEK, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Dignitana jaoks arvutada või ettevõte ei maksa dividende välja.

Dignitana ISIN on SE0002108001.

Dignitana WKN on A1JTEU.

Dignitana tähis on DIGN.ST.

Viimase 12 kuu jooksul maksis Dignitana dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Dignitana tõenäoliselt dividendi summas 0 SEK.

Dignitana praegune dividenditootlus on .

Dignitana maksab kvartaalset dividendi. See makstakse välja kuudel .

Dignitana maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 SEK. See vastab dividenditootlusele 0 %.

Dignitana on liigitatud sektorisse 'Tervis'.

Viimase Dignitana dividendide saamiseks 9.9.2024 suuruses 0 SEK pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 9.9.2024.

Viimane dividendimakse toimus 9.9.2024.

Aastal 2023 maksis Dignitana 0 SEK dividende.

Dignitana dividendid makstakse välja SEK.